Clinical trial results
Actor portrayals.
Discover what's possible with your RYBREVANT FASPRO™–based or RYBREVANT®-based treatment:
Almost twice as much
time
without cancer
getting
worse
Half of people taking RYBREVANT® + chemotherapy lived for an
average of 11.4 months without their cancer growing or spreading, while half of people taking just chemotherapy lived 6.7 months without their cancer growing or spreading.
Make tumors shrink or
disappear*
63% of people taking RYBREVANT® + chemotherapy had their tumors shrink, while 36% of people taking just chemotherapy had the same result.
Tumors disappeared in 4% of people taking RYBREVANT® + chemotherapy, and in 1% of people taking just chemotherapy.
What do these results mean if you've been prescribed RYBREVANT FASPRO™ + chemotherapy instead of RYBREVANT® + chemotherapy?
Whether you get your medicine as a RYBREVANT FASPRO™ injection or RYBREVANT® infusion, both ways are similarly helpful in treating your cancer.
Where did these results come from?
RYBREVANT® + chemotherapy was compared with chemotherapy alone in a clinical trial. A group of 308 people received either RYBREVANT® + chemotherapy or just chemotherapy as their first treatment for advanced NSCLC with exon 20 insertion mutations.
*When tumors shrink, they are measurably smaller but they can still be seen on scans by your doctor. And even if a tumor disappears, it does not necessarily mean the cancer has been cured.
EGFR+, mutated epidermal growth factor receptor; NSCLC, non–small cell lung cancer.
About side effects
Learn more about the side effects that you may experience during treatment with RYBREVANT FASPRO™ + chemotherapy or RYBREVANT® + chemotherapy.
Savings & support
Once prescribed RYBREVANT FASPRO™ or RYBREVANT®, connect with a Care Navigator for your support needs.
;